LakeShore Biopharma details move to OTC market

LakeShore Biopharma Co., Ltd filed a Form 6-K as a foreign private issuer, mainly to furnish a press release about its stock trading status.

Accepted by SEC EDGAR 09/22/2025 - 08:10 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

LakeShore Biopharma Co., Ltd filed a Form 6-K as a foreign private issuer, mainly to furnish a press release about its stock trading status. The company announced a transition to trading on the OTC market following a Nasdaq delisting. The report is signed by Director and Chief Financial Officer Rachel Yu on September 22, 2025.

Positive

• None.

Negative

• Nasdaq delisting and OTC transition: The company furnished a press release titled "LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting," indicating a move away from a major exchange to an over-the-counter market, which typically reflects a weaker listing status.

Insights

Equity markets & listing analyst

Nasdaq delisting and OTC move signal reduced listing status.

LakeShore Biopharma reports that it is transitioning to the OTC market after a Nasdaq delisting, as described in a press release furnished with this Form 6-K. This represents a step down from a major U.S. exchange to an over-the-counter venue.

Moving from Nasdaq to an OTC market often means lower visibility and potentially less trading liquidity, although exact trading impact is not detailed here. The filing itself is administrative, but the referenced delisting and venue change are significant listing developments for shareholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does LakeShore Biopharma (LSBPW) report in this Form 6-K?

LakeShore Biopharma uses this Form 6-K to furnish a press release describing its transition to trading on the OTC market following a Nasdaq delisting. The filing is an informational update for investors as a foreign private issuer.

What major change does LakeShore Biopharma (LSBPW) disclose about its listing?

The company discloses, via a referenced press release, that it is transitioning to the OTC market after a Nasdaq delisting. This highlights a shift from a major U.S. exchange to over-the-counter trading for its securities.

When was the LakeShore Biopharma (LSBPW) Form 6-K signed and by whom?

The Form 6-K was signed on September 22, 2025 by Rachel Yu, who is identified as a Director and Chief Financial Officer of LakeShore Biopharma Co., Ltd. Her signature confirms the company’s authorization of the report.

What exhibit is attached to LakeShore Biopharma’s (LSBPW) Form 6-K?

The Form 6-K includes Exhibit 99.1, described as a press release titled "LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting." This exhibit contains the detailed announcement related to the listing change.

Is LakeShore Biopharma (LSBPW) a foreign private issuer in this filing?

Yes. The document is a Form 6-K report of a foreign private issuer, indicating LakeShore Biopharma files periodic information in this format rather than using standard domestic issuer forms like Form 10-K or Form 10-Q.

What is the purpose of a Form 6-K for LakeShore Biopharma (LSBPW)?

Form 6-K is used by LakeShore Biopharma as a foreign private issuer to provide important updates, such as the attached press release about its transition to the OTC market following Nasdaq delisting, to U.S. investors and regulators.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission file number: 001-41598

LAKESHORE BIOPHARMA CO., LTD

(Exact name of registrant as specified in its charter)

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F  ☒          Form 40-F  ☐

EXHIBITS

Exhibit No.		Description
99.1		Press Release - LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting

1

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LakeShore Biopharma Co., Ltd
	By:	/s/ Rachel Yu
	Name:	Rachel Yu
	Title:	Director and Chief Financial Officer

Date: September 22, 2025

2